Target intelligence / Profile preview

B-cell lymphoma extra-large (Bcl-xL)

Target
Bcl-xL
Molecular classification
Other
01

Overview

B-cell lymphoma extra-large (Bcl-xL), encoded by the BCL2L1 gene, is a key anti-apoptotic protein belonging to the Bcl-2 family. Located primarily on the outer mitochondrial membrane, Bcl-xL plays a critical role in promoting cell survival by binding and sequestering pro-apoptotic proteins such as Bax, Bak, and BH3-only proteins, thereby preventing mitochondrial outer membrane permeabilization and the subsequent release of cytochrome c. In many human cancers, Bcl-xL is overexpressed, allowing malignant cells to evade apoptosis and develop resistance to chemotherapy and radiation. Consequently, Bcl-xL has emerged as an attractive therapeutic target. However, the clinical utility of small-molecule Bcl-xL inhibitors, such as navitoclax, has been severely limited by dose-limiting, on-target thrombocytopenia, as platelets rely heavily on Bcl-xL for survival. To overcome this toxicity, researchers have developed novel strategies, including selective Bcl-xL proteolysis-targeting chimeras (PROTACs) like DT2216, which target Bcl-xL for degradation via E3 ligases that are poorly expressed in platelets.

Other names
Bcl-2-like protein 1Apoptosis regulator Bcl-XBCL2L1BCL-XLBcl-X(L)
02

Mechanism of action

Inhibition of Bcl-xL anti-apoptotic activity by mimicking BH3-only proteins (BH3 mimetics) to disrupt interactions with pro-apoptotic proteins like Bax and Bak, or targeted degradation of Bcl-xL using proteolysis-targeting chimeras (PROTACs).

03

Biological functions

ApoptosisCell deathCell cycleOther
04

Disease associations

CancerOther
05

Safety considerations

ThrombocytopeniaNeutropeniaLymphopenia
06

Interacting drugs

8 more in the full profile.

07

Biomarkers

BCL2L1 gene amplificationBcl-xL protein expressionBcl-xL mRNA expressionBRAF mutation statusBH3 profiling

Beyond the preview

Go deeper on B-cell lymphoma extra-large (Bcl-xL).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on B-cell lymphoma extra-large (Bcl-xL).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call